Screener
Ionis Pharmaceuticals IONS Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Investment income | 20,230 | 24,687 | 45,713 | 49,354 |
| Interest expense | (4,618) | (4,114) | (9,778) | (8,223) |
| Interest expense related to sale of future royalties | (17,506) | (18,648) | (34,843) | (37,470) |
| Gain (loss) on investments, net | (10,182) | (18,312) | 12,401 | (20,476) |
| Other income, net | 987 | 102 | 529 | 569 |
| Income (loss) before income tax benefit (expense) | (113,382) | 123,531 | (205,692) | (23,291) |
| Income tax benefit (expense) | (1,264) | 20 | (1,482) | (96) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported interest expense and amortization of issuance costs related to sale of future royalties of $17.51M in Q2 2026.
- How has Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties changed year-over-year?
- Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties decreased by 6.1% year-over-year, from $18.65M to $17.51M.
- What does interest expense and amortization of issuance costs related to sale of future royalties mean?
- Specifically captures interest costs and the amortization of issuance costs related to financing arrangements involving the sale of future royalties. This is a specialized financing cost unique to companies that monetize future revenue streams.
Ask your AI about Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude